Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Keiichi Ota, Koichi Azuma, Akihiko Kawahara, +11

Clinical Cancer Research

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka, +19

Annals of Oncology

Tumor Immune MicroenvironmentCancer ImmunosurveillanceMedicineImmunologyTumor Immunity +9

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, +14

Clinical Cancer Research

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, +10

Journal of Thoracic Oncology

Biomarker (Medicine)Prognostic BiomarkersOncologyMedicineBiomarker Target +7

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Li Tan, Jun Wang, Junko Tanizaki, +20

Proceedings of the National Academy of Sciences

Covalent InhibitorsFgfr InhibitorsHuman Fgf ReceptorsMolecular BiologyPharmacotherapy +16

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, +11

Investigational New Drugs

Nivolumab-related CholangitisBiliary CancerHistopathologyGastroenterologyPathology +7

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, +10

Clinical Cancer Research

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal, +13

Cancer Research

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Junko Tanizaki, Isamu Okamoto, Kunio Okamoto, +4

Journal of Thoracic Oncology

MedicineMetronomic TherapyPharmacologyPathologyDifferential Antitumor Effects +8

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

Junko Tanizaki, Isamu Okamoto, Kazuko Sakai, +1

British Journal of Cancer